"The automated scoring of Clever-1 positive cells sped up the pathological scoring of our tissue samples, which we are routinely staining as part of our ongoing clinical trials. Pathologists at a contract research organization currently do this work, and the availability of pathologists is often a limiting factor in obtaining timely results. This research project will help us identify patients who can benefit from our experimental cancer treatment, so we foresee promise in Aiforia as our companion in diagnostic development."
"Aiforia is one of the top companies implementing methodologies to develop specific AI-based algorithms applicable to the research that we are conducting."